GUEVARA RAMIREZ, ALEXANDRA PATRICIAALEXANDRA PATRICIAGUEVARA RAMIREZTAMAYO TRUJILLO, VICTOR RAFAELVICTOR RAFAELTAMAYO TRUJILLORuiz Pozo Viviana A.CADENA ULLAURI, SANTIAGO ANDRESANTIAGO ANDRECADENA ULLAURIPAZ CRUZ, ELIUS ANDRESELIUS ANDRESPAZ CRUZZAMBRANO ESPINOSA, ANA KARINAANA KARINAZAMBRANO ESPINOSA2025-07-282025-07-282025-07-07https://doi.org/10.3390/ijms26136537<jats:p>Autism spectrum disorder (ASD) is a neurodevelopmental condition frequently associated with gastrointestinal symptoms, gut dysbiosis, and metabolic dysfunctions such as insulin resistance (IR). Recent evidence suggests that the gut microbiota may influence both metabolic and neurological processes through the gut–brain–metabolic axis. This review explores the molecular mechanisms linking dysbiosis, IR, and ASD, focusing on pathways such as TLR/NF-κB activation, PI3K/Akt/mTOR disruption, and the action of microbial metabolites, like short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and γ-aminobutyric acid (GABA). We discuss how dysbiosis may contribute to increased intestinal permeability, systemic inflammation, and neuroimmune activation, ultimately affecting brain development and behavior. Common microbial alterations in ASD and IR—including increased Clostridium, Desulfovibrio, and Alistipes, and reduced Bifidobacterium and butyrate-producing genera—suggest a shared pathophysiology. We also highlight potential therapeutic strategies, such as microbiota modulation, insulin-like growth factor 1 (IGF-1) treatment, and dietary interventions. Understanding these interconnected mechanisms may support the development of microbiota-targeted approaches for individuals with ASD metabolic comorbidities.</jats:p>Atención médicaTrastorno del espectro autistaMicrobiotaResistencia a la insulinaVías molecularesjournal-article